Merck announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer met its dual primary endpoint of overall survival. At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery, followed by resection and KEYTRUDA as a single agent after surgery, demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified. Full results from this analysis of KEYNOTE-671 will be presented at the European Society for Medical Oncology Congress 2023 and shared with regulatory authorities worldwide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck announces AMBASSADOR trial meets one of two primary endpoints of DFS
- Merck’s new application for sotatercept given priority review by FDA
- Unusually active option classes on open September 26th
- Merck, Eisai provide update on Phase 3 trials, LEAP-006 and LEAP-008
- Merck confirms Phase 3 KEYNOTE-A39/EV-302 trial met dual primary endpoints